Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors

PURPOSE: There are few effective therapies for pancreatic neuroendocrine tumors (PNETs). Recent placebo-controlled phase III trials of the mammalian target of rapamycin (mTOR) inhibitor everolimus and the vascular endothelial growth factor (VEGF)/platelet-derived growth factor receptor inhibitor sun...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Hobday, Timothy J., Qin, Rui, Reidy-Lagunes, Diane, Moore, Malcolm J., Strosberg, Jonathan, Kaubisch, Andreas, Shah, Manisha, Kindler, Hedy Lee, Lenz, Heinz-Josef, Chen, Helen, Erlichman, Charles
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2015
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4417726/
https://ncbi.nlm.nih.gov/pubmed/25488966
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2082
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires